Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Scientists Race To Improve 'Living Drugs' To Fight Cancer

(NPR/Shots blog) Aug 16, 2018 - Aaron Reid is lying in a hospital bed at the National Institutes of Health when doctors arrive to make sure he's ready for his experimental treatment. "How's your night? Any issues?" asks Dr. Katherine Barnett, a pediatric oncologist, as they begin to examine Reid. Reid, 20, of Lucedale, Miss., has been fighting leukemia ever since he was nine years old. He's been through chemotherapy and radiation twice, a bone marrow transplant and two other treatments.

read article

Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

(Markets Insider) Aug 16, 2018 - Trovagene, Inc. today announced completion of the second dosing cohort of Onvansertib, a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care low-dose cytarabine (LDAC), in its Phase 1b/2 clinical trial in patients with Acute Myeloid Leukemia (AML).

read article

Stress Hormone Is Key Factor In Failure Of Immune System To Prevent Leukemia

(University of Kent [UK]) Aug 14, 2018 - The human stress hormone cortisol has been identified by scientists at the University as a key factor when the immune system fails to prevent leukemia taking hold.

read article

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring

(URMC) Aug 13, 2018 - While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer.

read article

NHS Scraps Restriction On Availability Of J&J's Imbruvica In Leukaemia Patients

(Pharmafile [UK]) Aug 10, 2018 - The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), expanding its use to cover treatment-naïve patients with chronic lymphoblastic forms of the condition (CLL).

read article

NICE Changes Its Mind On Pfizer’s Besponsa

(PharmaTimes [UK]) Aug 9, 2018 - Following an appeal the drug will now be available to treat ALL.

read article

Increased Risk Of Myeloid Blood Cancers In Relatives Of Patients

(ICR [UK]) Aug 7, 2018 - The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients.

read article

MD Anderson and Jazz Pharmaceuticals Collaborate To Evaluate Potential Treatment Options For Hematologic Malignancies

(MD Anderson) Aug 6, 2018 - The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.

read press release

Comprehensive CAR T-cell Therapy Pediatric Guidelines Developed by MD Anderson in Collaboration with the Pediatric Acute Lung Injury and Sepsis Investigators Network

(MD Anderson) Aug 6, 2018 - Researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing CAR T-cell therapy for children with acute lymphoblastic leukemia (ALL).

read press release

Taking A Glimpse At The MLL1 Gene

(UCCC/Colorado Cancer Blogs) Aug 2, 2018 - Discovering why young people are prone to certain kinds of cancer, relative to adults, reveals important insights about cancer that can benefit both groups.

read article

CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

(Markets Insider) Aug 3, 2018 - Jazz Pharmaceuticals plc today announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for Vyxeos® (daunorubicin and cytarabine) liposome for injection for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), a rapidly progressing and life-threatening blood cancer.

read article

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

(Daiichi Sankyo) Aug 1, 2018 - Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). “There have been limited advances over the past several decades for the treatment of relapsed/refractory FLT3-ITD AML, a very aggressive form of the disease associated with poor prognosis. Quizartinib is the first FLT3 inhibitor to significantly improve overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory AML with FLT3-ITD, an underlying driver of this subtype of AML,” said Arnaud Lesegretain, Vice President, Oncology Research and Development and Head, AML Franchise, Daiichi Sankyo. “We are excited that quizartinib has received Breakthrough Therapy designation and we look forward to working closely with the FDA to bring this potential new treatment option to patients as quickly as possible.”

read corporate press release

Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1 Study of Guadecitabine (SGI-110) in Treatment-Naïve AML Patients Ineligible to Receive Intense Induction Chemotherapy

(Morningstar) July 30, 2018 - Guadecitabine did not meet the co-primary endpoints of complete response (CR) rate or overall survival (OS) in the ASTRAL-1 study. Astex continues to focus on completing the phase 3 ASTRAL-2 and ASTRAL-3 studies evaluating the efficacy and safety of guadecitabine in relapsed and refractory acute myeloid leukemia (R/R AML) and relapsed and refractory myelodysplastic syndromes (R/R MDS) and chronic myelomonocytic leukemia (CMML). Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASTRAL-1 study evaluating the efficacy and safety of guadecitabine (SGI-110) in adults with previously untreated AML who are not eligible for intensive induction chemotherapy.

read article

Chinese Leukemia Patient Livestreams to Pay for Treatment

(New York Times) July 30, 2018 - At least once a week, Su Lingmin films herself singing, sharing health tips and chatting with hundreds of fans from her hospital bed.

read article

‘Hijacked’ Cell Response to Stress Reveals Promising Drug Targets for Blood Cancer

(NYU Langone Health) July 23, 2018 - A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a study shows.

read press release

Tolero Pharmaceuticals Advances Investigational Agent Alvocidib into Second Stage of Phase 2 Zella 201 Study in Patients with Relapsed Refractory MCL-1-Dependent AML

(Morningstar) July 23, 2018 - Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that it has initiated the second stage of the Phase 2 Zella 201 study evaluating the efficacy and safety of alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and mitoxantrone (ACM) in patients with relapsed or refractory MCL-1-dependent acute myeloid leukemia (AML).

read article

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

(Agios) July 20, 2018 - Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that TIBSOVO® (ivosidenib) was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. TIBSOVO®, an oral, targeted inhibitor of the IDH1 enzyme, is the first and only FDA-approved therapy for patients with R/R AML and an IDH1 mutation. “The FDA approval of TIBSOVO® – our first wholly owned drug and the second approved medicine from our research platform in less than a year – is an incredibly exciting milestone for our company and, importantly, for the approximately 6-10% of AML patients with an IDH1 mutation who have been waiting for new treatment options that work radically different than conventional chemotherapy,” said David Schenkein, M.D., chief executive officer at Agios.

read corporate press release

CT Imaging in Kids Raises Cancer Risk

(MedPage Today) July 18, 2018 - Pediatric patients who had CT scans had a higher-than-expected risk of developing cancer later in life, results of a large retrospective Dutch study suggested.

read article (free registration required)

Cellectar Biosciences Skyrockets On Positive Data In Cancer Trial

(NASDAQ) July 17, 2018 - Clinical stage biopharmaceutical company Cellectar Biosciences, said a patient with a rare type of cancer that begins in the white blood cells, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses, in a mid-stage cancer study. CLRB is currently trading up 1365.95% at $10.98.

read article

New Research Shows Promise in Regional Delivery of CAR-T Therapy

(MarketWatch) July 13, 2018 - Surefire Medical, Inc., an oncology drug delivery company, announced the publication of “Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy” in the ISSUE of the Journal of Interventional Radiology.

read article
Next Page